GlassScriptPhysician profile
John MD Lucas
NPI 1316507684
$2,348.82
in general payments reported to CMS, 2019-2025
17 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2021: $417 · 2022: $338 · 2023: $844 · 2024: $491 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $592.62 | 2021-2024 | |
| Kerecis Limited | $274.49 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Acera Surgical, INC. | $260.83 | 2019-2024 | Restrata Wound Matrix |
| Zimmer Biomet Holdings, INC. | $204.23 | 2023-2025 | Advantagerib |
| Davol INC. | $183.69 | 2022-2024 | Phasix Mesh |
| Nuvasive, INC. | $154.18 | 2023 | Xlif, Reline, Tlif |
| Abbvie INC. | $127.90 | 2021-2025 | |
| Medtronic, INC. | $90.96 | 2024 | Signia |
| Octapharma USA, INC. | $90.12 | 2023 | Panzyga |
| Teva Pharmaceuticals USA, INC. | $85.71 | 2023-2024 | Austedo Xr, Austedo |
| Depuy Synthes Sales INC. | $67.91 | 2023 | Matrixrib, Zipfix, Xcm Biologic Tissue Matrix |
| Sunovion Pharmaceuticals INC. | $62.42 | 2021 | |
| Livanova USA, INC. | $48.84 | 2021-2022 | |
| Integra Lifesciences Corporation | $42.11 | 2023 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Mdd US Operations, LLC | $26.12 | 2023 | Gocovri |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.05 | 2023 | Reyvow, Emgality |
| Supernus Pharmaceuticals, INC. | $16.64 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.